USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered premarin therapy is contraindicated in individuals with any of the following conditions: premarin should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. premarin should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectable amounts of estrogens have been identified in the breast milk of mothers receiving estrogen-alone therapy. caution should be exercised when premarin is administered to a nursing woman. estrogen therapy has been used for the induction of puberty in adolescents with some forms of pubertal delay. safety and effectiveness in pediatric patients have not otherwise been established. large and repeated doses of estrogen over an extended time period have been shown to accelerate epiphyseal closure, which could result in short stature if treatment is initiated before the completion of physiologic puberty in normally developing children. if estrogen is administered to patients whose bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended during estrogen administration. estrogen treatment of prepubertal girls also induces premature breast development and vaginal cornification, and may induce vaginal bleeding. in boys, estrogen treatment may modify the normal pubertal process and induce gynecomastia. there have not been sufficient numbers of geriatric patients involved in studies utilizing premarin to determine whether those over 65 years of age differ from younger subjects in their response to premarin. the women's health initiative study in the whi estrogen-alone substudy (daily ce 0.625 mg-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.5)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg]), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.5)] . the women's health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.3), and clinical studies (14.6)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see warnings and precautions (5.3), and clinical studies (14.6)]. the effect of renal impairment on the pharmacokinetics of premarin has not been studied. the effect of hepatic impairment on the pharmacokinetics of premarin has not been studied.

USA - engelsk - NLM (National Library of Medicine)

energique, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), estriol (unii: fb33469r8e) (estriol - unii:fb33469r8e), estrone (unii: 2di9ha706a) (estrone - unii:2di9ha706a) - for temporary relief of symptoms associated with estrogen imbalances such as excessive bleeding, irregular menses, fertility issues, difficulties in labor and breast-feeding, depression, hot flashes and vaginal dryness and irritation.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. for temporary relief of symptoms associated with estrogen imbalances such as excessive bleeding, irregular menses, fertility issues, difficulties in labor and breast-feeding, depression, hot flashes and vaginal dryness and irritation.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

USA - engelsk - NLM (National Library of Medicine)

problen - chaste tree (unii: 433osf3u8a) (chaste tree - unii:433osf3u8a), angelica sinensis root (unii: b66f4574ug) (angelica sinensis root - unii:b66f4574ug), apis mellifera (unii: 7s82p3r43z) (apis mellifera - unii:7s82p3r43z), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), black cohosh (unii: k73e24s6x9) (black cohosh - unii:k73e24s6x9), estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), estriol (unii: fb33469r8e) (estriol - unii:fb33469r8e), estrone (unii: 2di9ha706a) (estr - chaste tree 3 [hp_x] in 1 ml - temporarily supports the body to rebalance estrogen output.  symptoms may include: mood swings, hot flashes, irritability, lack of energy. temporarily supports the body to rebalance estrogen output. symptoms may include: mood swings, hot flashes, irritability, lack of energy.

USA - engelsk - NLM (National Library of Medicine)

problen - agnus castus 3x, angelica sinensis, apis mellifica 6x, arnica montana 6x, cimicifuga racemosa 3x, estradiol 9c, estriol 9c, folliculinum 9c, galium aparine 3x, glycyrrhiza glabra 3x, korean ginseng 3x, oophorinum suis 30c, progesterone 6x, sepia 30c, thuja occidentalis 6x, viscum album 3x - temporarily supports the body to rebalance estrogen output. symptoms may include: mood swings, hot flashes, irritability, lack of energy. temporarily supports the body to rebalance estrogen output. symptoms may include: mood swings, hot flashes, irritability, lack of energy.

USA - engelsk - NLM (National Library of Medicine)

problen - chaste tree (unii: 433osf3u8a) (chaste tree - unii:433osf3u8a), angelica sinensis root (unii: b66f4574ug) (angelica sinensis root - unii:b66f4574ug), apis mellifera (unii: 7s82p3r43z) (apis mellifera - unii:7s82p3r43z), black cohosh (unii: k73e24s6x9) (black cohosh - unii:k73e24s6x9), estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), estriol (unii: fb33469r8e) (estriol - unii:fb33469r8e), estrone (unii: 2di9ha706a) (estrone - unii:2di9ha706a), galium aparine (unii: z4b6561488) (galium aparine - un - ​indications: ​temporarily supports the body to rebalance estrogen output. symptoms may include: mood swings, hot flashes, irritability, lack of energy.

USA - engelsk - NLM (National Library of Medicine)

energique, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - may temporarily relieve symptoms associated with reactions to estrogen, such as breast tenderness and menopausal symptoms.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve symptoms associated with reactions to estrogen, such as breast tenderness and menopausal symptoms.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Canada - engelsk - Health Canada

pfizer canada ulc - conjugated estrogens; medroxyprogesterone acetate - kit - 0.625mg; 2.5mg - conjugated estrogens 0.625mg; medroxyprogesterone acetate 2.5mg - estrogens

Canada - engelsk - Health Canada

pfizer canada ulc - conjugated estrogens; medroxyprogesterone acetate - kit - 0.625mg; 5mg - conjugated estrogens 0.625mg; medroxyprogesterone acetate 5mg - estrogens

Canada - engelsk - Health Canada

pfizer canada ulc - conjugated estrogens; medroxyprogesterone acetate - kit - 0.625mg; 10mg - conjugated estrogens 0.625mg; medroxyprogesterone acetate 10mg - estrogens

Canada - engelsk - Health Canada

pfizer canada ulc - conjugated estrogens - cream - 0.625mg - conjugated estrogens 0.625mg - estrogens